Page 22 - Read Online

Di Raimo et al. J Cancer Metastasis Treat 2018;4:54 I http://dx.doi.org/10.20517/2394-4722.2018.50 Page 13 of 14

145. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, et al. Inertial focusing for tumor antigen-dependent and -independent
sorting of rare circulating tumor cells. Sci Transl Med 2013;5:179ra47.
146. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-
chip. Proc Natl Acad Sci U S A 2010;107:18392-7.
147. Harb W, Fan A, Tran T, Danila DC, Keys D, et al. Mutational analysis of circulating tumor cells using a novel microfluidic collection device
and qPCR assay. Transl Oncol 2013;6:528-38.
148. Kalinsky K, Mayer JA, Xu X, Pham T, Wong KL, et al. Correlation of hormone receptor status between circulating tumor cells, primary
tumor, and metastasis in breast cancer patients. Clin Transl Oncol 2015;17:539-46.
149. Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K, et al. Optimization and evaluation of a novel size based circulating tumor cell isolation
system. PLoS One 2015;10:e0138032.
150. Sollier E, Go DE, Che J, Gossett DR, O’Byrne S, et al. Size-selective collection of circulating tumor cells using Vortex technology. Lab
Chip 2014;14:63-77.
151. Khoo BL, Warkiani ME, Tan DS, Bhagat AA, Irwin D, et al. Clinical validation of an ultra high-throughput spiral microfluidics for the
detection and enrichment of viable circulating tumor cells. PLoS One 2014;9:e99409.
152. Gerges N, Rak J, Jabado N. New technologies for the detection of circulating tumour cells. Br Med Bull 2010;94:49-64.
153. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. Circulating tumor cells, disease progression, and survival in metastatic breast
cancer. N Engl J Med 2004;351:781-91.
154. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, et al. Isolating highly enriched populations of circulating epithelial cells and other
rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 2009;106:3970-5.
155. Chinen LT, de Carvalho FM, Rocha BM, Aguiar CM, Abdallah EA, et al. Cytokeratin-based CTC counting unrelated to clinical follow up. J
Thorac Dis 2013;5:593-9.
156. Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor
tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection
technology. Breast Cancer Res Treat 2011;128:155-63.
157. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, et al. Comparison of assay methods for detection of circulating tumor
cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer
2012;130:1590-7.
158. López-Riquelme N, Minguela A, Villar-Permuy F, Ciprian D, Castillejo A, et al. Imaging cytometry for counting circulating tumor cells:
comparative analysis of the CellSearch vs ImageStream systems. APMIS 2013;121:1139-43.
159. Magbanua MJ, Park JW. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/
FACS) for molecular profiling. Methods 2013;64:114-8.
160. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, et al. Genomic profiling of isolated circulating tumor cells from metastatic breast
cancer patients. Cancer Res 2013;73:30-40.
161. Morris RJ. Circulating tumor cells: quintessential precision oncology presenting challenges for biology. NPJ Precis Oncol 2017;1:16.
162. Wallwiener M, Riethdorf S, Hartkopf AD, Modugno C, Nees J, et al. Serial enumeration of circulating tumor cells predicts treatment
response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer 2014;14:512.
163. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised RECIST
guideline (version 1.1). Eur J Cancer 2009;45:228-47.
164. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, et al. Epithelial-mesenchymal transition and stemness features in circulating
tumor cells from breast cancer patients. Breast Cancer Res Treat 2011;130:449-55.
165. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-
positive metastatic breast cancer. Mol Cancer Ther 2012;11:2526-34.
166. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, et al. Characterization of metastatic breast cancer patients with nondetectable
circulating tumor cells. Int J Cancer 2011;129:417-23.
167. Satelli A, Batth I, Brownlee Z, Mitra A, Zhou S, et al. EMT circulating tumor cells detected by cell-surface vimentin are associated with
prostate cancer progression. Oncotarget 2017;8:49329-37.
168. Serrano MJ, Ortega FG, Alvarez-Cubero MJ, Nadal R, Sanchez-Rovira P, et al. EMT and EGFR in CTCs cytokeratin negative non-
metastatic breast cancer. Oncotarget 2014;5:7486-97.
169. Duffy MJ, McDermott EW, Crown J. Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor
DNA. Tumour Biol 2018;40:1010428318776169.
170. Austin RG, Huang TJ, Wu M, Armstrong AJ, Zhang T. Clinical utility of non-EpCAM based circulating tumor cell assays. Adv Drug Deliv
Rev 2018;125:132-42.
171. Khatami F, Aghayan HR, Sanaei M, Heshmat R, Tavangar SM, et al. The potential of circulating tumor cells in personalized management of
breast cancer: a systematic review. Acta Med Iran 2017;55:175-93.
172. Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different
molecular subtypes of breast cancer. PLoS One 2015;10:e0133830.
173. Gion M, Mione R, Barioli P, Sartorello P, Capitanio G. Tissue polypeptide antigen and tissue polypeptide specific antigen in primary breast
cancer. Evaluation in serum and tumour tissue. Eur J Clin Chem Clin Biochem 1994;32:779-87.
174. Tchou J, Lam L, Li YR, Edwards C, Ky B, et al. Monitoring serum HER2 levels in breast cancer patients. Springerplus 2015;4:237.
175. Mokuyasu S, Suzuki Y, Seto T, Miyachi H, Tokuda Y. A comparative clinical evaluation of the assay of serum extracellular domain of
HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in
immunohistochemistry. Rinsho Byori 2012;60:612-20.
176. Fujimoto Y, Higuchi T, Nishimukai A, Miyagawa Y, Kira A, et al. High levels of serum CA15-3 and residual invasive tumor size are